NCT04510662View on ClinicalTrials.gov

Telmisartan in Respiratory Failure Due to COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 12, 2020

Primary Completion Date

May 15, 2021

Study Completion Date

May 25, 2021

Conditions
COVID-19Respiratory InsufficiencyTelmisartanRespiratory Distress Syndrome, Adult
Interventions
DRUG

Telmisartan

Patients in this group will receive telmisartan 40 mg daily plus standard care.

Trial Locations (1)

55600

Hospital Regional de Alta Especialidad de Zumpango, Zumpango

All Listed Sponsors
collaborator

National Polytechnic Institute, Mexico

OTHER

lead

Abraham Edgar Gracia-Ramos

OTHER_GOV

NCT04510662 - Telmisartan in Respiratory Failure Due to COVID-19 | Biotech Hunter | Biotech Hunter